The Global Gaucher disease drugs market size stood at USD 2.5 billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
Gaucher disease is an inherited disorder resulting build-up of certain fatty substance in certain organ, mainly in liver, bone marrow and spleen. It is the most common lysosomal storage disorders. Due to the low level of glucocerebrosidase an enzyme that breaks down the fatty chemical in the body known as glucocerebroside. Gaucher cells are normal scavenger cells known as macrophages that become full of unprocessed glucocerebroside. These unprocessed Gaucher cells accumulate primarily in the sleep, liver and bone marrow and causes serious orang dysfunction and inflammation. Each pregnant female has a 1 in 4 chance that the baby will be born with the disease. People with Gaucher disease carrier status do not have signs or symptoms. Symptoms of Gaucher disease include skeletal abnormalities, blood disorders and abdominal complaints
The market is likely to exhibit modest growth during the forecast period. Rising incidence of the disease and increasing efforts for the identification of more GD patients are among the primary growth stimulants for the market
Lack of drugs in the late-stage pipeline and the rising cost of treatment are limiting the market from realizing its utmost potential. There remains a high unmet need for the development of improved treatments that combat neuronopathic complications at reduced costs and convenient administration schedules. Nevertheless, increasing investments in research and development activities related to rare diseases are projected to shape the future of the market